Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIF5B | P33176 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13911374 | 0.89 | BCL2L1 (0.46) | DRD2DRD1DRD5DRD3RET | |
| SCHEMBL24873677 | 0.78 | NOTUM (0.38) | NOTUMMGLL | |
| SCHEMBL13462411 | 0.78 | S1PR1 (0.37) | NOTUMMGLL | |
| SCHEMBL256749 | 0.78 | NOTUM (0.56) | DRD2NOTUMSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16720228 | 0.77 | S1PR1 (0.34) | DRD2DRD1DRD5DRD3RET | |
| SCHEMBL2625772 | 0.76 | NOTUM (0.57) | DRD2DRD3NOTUM | |
| SCHEMBL25044260 | 0.76 | KDM4E (0.35) | DRD2DRD3NOTUMMGLL | |
| SCHEMBL2484100 | 0.76 | ADRA2C (0.44) | NOTUMSLC6A2SLC6A4SLC6A3MGLL | |
| SCHEMBL2625776 | 0.76 | NOTUM (0.57) | NOTUM | |
| SCHEMBL25124822 | 0.76 | AKT1 (0.37) | DRD2DRD1DRD5DRD3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | claimed |
| US-6723136-B2 | PRECURSOR OF AROMATIC RINGS HAVING HYDROXYL GROUPS ON ADJACENT CARBON ATOMS, AND OXIDATION BASE OF PARA OR ORTHO AROMATIC AMINES, AND A CATALYTIC SYSTEM OF SALTS AND OXIDES OF MANGANESE AND ZINC | L'OREAL (FR) | 2004-04-20 | — | — | US | claimed |
| US-20020124330-A1 | Coloration composition, process for obtaining the same and its use for the coloration of keratin fibres | L'OREAL (FR) | 2002-09-12 | — | — | US | claimed |
| EP-3113753-B2 | AQUEOUS OXIDIZING COMPOSITION FOR HAIR | KAO GERMANY GMBH (DE) | 2026-03-18 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-3113753-B1 | AQUEOUS OXIDIZING COMPOSITION FOR HAIR | KAO GERMANY GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3113748-B1 | PROCESS FOR MANUFACTURING AN EMULSION | KAO GERMANY GMBH (DE) | 2021-05-12 | — | — | EP | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020156162-A1 | MEK INHIBITOR AND PHARMACEUTICAL USE THEREOF | 贝达药业股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| CN-111148744-A | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3113847-B1 | ANHYDROUS DYEING COMPOSITION AND PROCESS FOR DYEING HAIR | KAO GERMANY GMBH (DE) | 2019-11-20 | — | — | EP | disclosed |
| EP-1627666-A1 | Composition for dyeing keratin fibres | KPSS-Kao Professional Salon Services GmbH (DE) | 2006-02-22 | — | — | EP | disclosed |
| US-20050257331-A1 | Composition for dyeing of keratin fibres | KPSS-KAO PROFESSIONAL SALON SERVICES GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050257334-A1 | Composition for dyeing keratin fibers | KPSS-KAO PROFESSIONAL SALON SERVICES GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1598052-A1 | Composition for bleaching and dyeing keratin fibres | KPSS-Kao Professional Salon Services GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1559403-A1 | Composition for dyeing human hair | KPSS-Kao Professional Salon Services GmbH (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-6002018-A | N-substituted 4-hydroxyindoline derivatives | L'OREAL (FR) | 1999-12-14 | — | — | US | disclosed |
| US-5755829-A | HAIR DYES USING HYDROXYINDOLE COUPLERS AND OXIDATION BASES | L'OREAL (FR) | 1998-05-26 | — | — | US | disclosed |
| EP-0780118-B1 | Compositions for dyeing keratinous fibers containing N-substituted 4-hydroxy indoline derivatives, and certain of these derivatives | OREAL (FR) | 1997-12-29 | — | — | EP | disclosed |
| EP-0780118-A1 | Compositions for dyeing keratinous fibers containing N-substituted 4-hydroxy indoline derivatives, and certain of these derivatives | L'OREAL (FR) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050257331-A1 | Composition for dyeing of keratin fibres | KRT18, KCNH3, MT-CO3 | DRD2 1549/4885DRD1 1416/4885DRD5 340/4885 |
| US-20020124330-A1 | Coloration composition, process for obtaining the same and its use for the coloration of keratin fibres | KRT18, TYR, OAT | DRD2 4569/4885DRD1 4591/4885DRD5 4521/4885 |
| US-20050257334-A1 | Composition for dyeing keratin fibers | KRT18, H1-5, CYB5R3 | DRD2 1548/4885DRD1 1200/4885DRD5 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.